Absci Corp 8-K

What Happened

• Absci Corporation filed an 8-K reporting that Chief Innovation Officer Andreas Busch, Ph.D., informed the company of his retirement effective March 31, 2026 and will transition to a scientific advisor role effective April 3, 2026. The company also announced the appointment of Ransi Somaratne, M.D., as Chief Medical Officer effective March 3, 2026.
• On March 6, 2026 the Board approved and the company entered into amended and restated director and officer indemnification agreements with its current directors and officers, updating the company’s standard indemnification terms.

Key Details

• Dr. Busch’s advisor engagement: a two-year term beginning April 3, 2026, unless earlier terminated.
• Advisor pay and equity: $25,500 annual retainer (paid quarterly, prorated as needed), plus stock options for 22,800 shares and 5,800 restricted stock units.
• Vested options amendment: 2,489,290 vested options held by Dr. Busch are amended to allow exercise until the earlier of (i) three months after termination of the Advisor Agreement (twelve months if termination due to death/disability; immediate termination if for cause) and (ii) the original option expiration date. Any options unvested as of the retirement date will terminate.
• Indemnification updates: revisions include more specific “change in control” language, coverage for an officer’s separate counsel expenses in a change-in-control, an express presumption of good faith for officers (burden on challenger), and an exclusion of indemnification for incentive/equity compensation under SEC Rule 10D-1.

Why It Matters

• Leadership continuity: the company retains Dr. Busch’s expertise via an advisory agreement while installing a new CMO, which may ease operational transition in R&D and clinical activities.
• Compensation and option changes: investors should note the material amendment extending exercise periods for ~2.49 million vested options (affects dilution timing and insider option exercise behavior) and the grant of new adviser equity.
• Governance protection: updated indemnification agreements strengthen protections for directors and officers and clarify change-in-control and counsel expense rules—relevant for executive risk management and corporate governance assessments.